Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes.

Gupta A, Bisht B, Dey CS.

Neuropharmacology. 2011 May;60(6):910-20. doi: 10.1016/j.neuropharm.2011.01.033. Epub 2011 Jan 26.

PMID:
21277873
2.

Insulin resistance and Alzheimer's disease: molecular links & clinical implications.

Neumann KF, Rojo L, Navarrete LP, Farías G, Reyes P, Maccioni RB.

Curr Alzheimer Res. 2008 Oct;5(5):438-47.

PMID:
18855585
4.

Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function.

Takeda S, Sato N, Rakugi H, Morishita R.

Mol Biosyst. 2011 Jun;7(6):1822-7. doi: 10.1039/c0mb00302f. Epub 2011 Mar 24. Review.

PMID:
21431241
5.

Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.

Bermúdez-Pirela VJ, Cano C, Medina MT, Souki A, Lemus MA, Leal EM, Seyfi HA, Cano R, Ciscek A, Bermúdez-Arias F, Contreras F, Israili ZH, Hernández-Hernández R, Valasco M.

Am J Ther. 2007 Mar-Apr;14(2):194-202.

PMID:
17414590
6.

PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance.

Gupta A, Dey CS.

Mol Biol Cell. 2012 Oct;23(19):3882-98. doi: 10.1091/mbc.E12-05-0337. Epub 2012 Aug 8.

7.

[Molecular action of insulin-sensitizing agents].

Kacalska O, Krzyczkowska-Sendrakowska M, Milewicz T, Zabińska-Popiela M, Bereza T, Krzysiek-Maczka G, Krzysiek J.

Endokrynol Pol. 2005 May-Jun;56(3):308-13. Review. Polish.

PMID:
16350724
9.

Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.

Zimmet P, Collier G.

Drugs. 1999;58 Suppl 1:21-8; discussion 75-82. Review.

PMID:
10576521
10.

Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes.

Subramanian S, John M.

Indian J Exp Biol. 2012 Jan;50(1):41-4.

PMID:
22279939
11.

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, Silverman MA, Kazi H, Melo HM, McClean PL, Holscher C, Arnold SE, Talbot K, Klein WL, Munoz DP, Ferreira ST, De Felice FG.

J Clin Invest. 2012 Apr;122(4):1339-53. doi: 10.1172/JCI57256.

12.
13.

Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer's-like phenotypes in mice.

Murakami K, Yokoyama S, Murata N, Ozawa Y, Irie K, Shirasawa T, Shimizu T.

Biochem Biophys Res Commun. 2011 May 27;409(1):34-9. doi: 10.1016/j.bbrc.2011.04.101. Epub 2011 Apr 28.

PMID:
21549686
14.

Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease.

Zhao WQ, Townsend M.

Biochim Biophys Acta. 2009 May;1792(5):482-96. doi: 10.1016/j.bbadis.2008.10.014. Epub 2008 Nov 5. Review.

15.

Rosiglitazone is more effective than metformin in improving fasting indexes of glucose metabolism in severely obese, non-diabetic patients.

Brunani A, Caumo A, Graci S, Castagna G, Viberti G, Liuzzi A.

Diabetes Obes Metab. 2008 Jun;10(6):460-7. Epub 2007 Mar 29.

PMID:
17394563
16.

Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease.

de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR.

J Alzheimers Dis. 2006 Sep;10(1):89-109. Review.

PMID:
16988486
17.

A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M.

J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):313-43. Epub 2006 Mar 22.

PMID:
16552630
18.

Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.

Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.

Metabolism. 2009 Aug;58(8):1059-66. doi: 10.1016/j.metabol.2009.03.007. Epub 2009 Jun 18.

PMID:
19394976
19.

Metformin/rosiglitazone combination pill (Avandamet) for the treatment of patients with Type 2 diabetes.

Smiley D, Umpierrez G.

Expert Opin Pharmacother. 2007 Jun;8(9):1353-64. Review.

PMID:
17563269
20.

Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.

Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM.

Gynecol Endocrinol. 2007 Mar;23(3):146-52.

PMID:
17454168
Items per page

Supplemental Content

Write to the Help Desk